Belvedere Trading
VKTX icon

Belvedere Trading’s Viking Therapeutics VKTX Stock Holding History

Belvedere Trading’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-7,700
Closed -$310K – 1010
2024
Q4 		$310K Hold
7,700
– – ﹤0.01% 324
2024
Q3 		$487K Sell
7,700
-100
-1% -$5.87K ﹤0.01% 197
2024
Q2 		$413K Sell
7,800
-1,500
-16% -$98.3K ﹤0.01% 214
2024
Q1 		$763K Buy
9,300
+4,900
+111% +$218K ﹤0.01% 114
2023
Q4 		$81.9K Sell
4,400
-3,500
-44% -$45.8K ﹤0.01% 494
2023
Q3 		$87.5K Sell
7,900
-7,600
-49% -$109K ﹤0.01% 354
2023
Q2 		$251K Buy
15,500
+2,200
+17% +$46.1K ﹤0.01% 262
2023
Q1 		$221K Sell
13,300
-7,900
-37% -$81.6K ﹤0.01% 302
2022
Q4 		$199K Buy
+21,200
New +$94.6K ﹤0.01% 334

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Belvedere Trading's VKTX Position: Q1 2025 in Review

Belvedere Trading sold out of Viking Therapeutics (VKTX) in Q1 2025, closing a stake of 1,098 shares — an estimated $44.2K sold.

Belvedere Trading first reported a position in VKTX in Q1 2023 and held it in 7 quarters. The position peaked at $2.96M in Q1 2024. 372 funds tracked by Wall St. Rank hold VKTX as of Q1 2025.

  • Belvedere Trading reported no remaining Viking Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Belvedere Trading sold 1,098 Viking Therapeutics shares in Q1 2025, an estimated $44.2K.
  • Belvedere Trading first reported a position in Viking Therapeutics in Q1 2023 and held it in 7 quarters.
  • Belvedere Trading's Viking Therapeutics position peaked at $2.96M in Q1 2024.
  • 372 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2025.

Based on Belvedere Trading's 13F filing for Q1 2025, filed 9 May 2025.